Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
Bristol Myers Squibb (BMY) reported stronger Q3 2025 results. Total revenues were $12.222 billion versus $11.892 billion a year ago, and diluted EPS rose to $1.08 from $0.60. Net earnings attributable to BMS were $2.201 billion.
The Growth Portfolio generated $6.857 billion, led by Opdivo $2.532 billion, Orencia $964 million, Yervoy $739 million, and newer brands like Reblozyl $615 million, Breyanzi $359 million, Camzyos $296 million, and Opdualag $299 million. The Legacy Portfolio totaled $5.365 billion: Eliquis $3.746 billion grew, while Revlimid fell to $575 million and Pomalyst/Imnovid to $675 million.
Operating cash flow for the first nine months reached $12.182 billion, cash and equivalents increased to $15.726 billion, and long‑term debt was $44.469 billion. The company recorded Q3 Acquired IPRD of $633 million and highlighted strategic moves: a $1.5 billion upfront to BioNTech, a $350 million upfront to Philochem, and a $250 million milestone to SystImmune. BMS completed the 2seventy bio acquisition for $287 million and announced an agreement to acquire Orbital Therapeutics for $1.5 billion, subject to customary closing conditions. Restructuring charges are expected to total approximately $2.5 billion through 2027, with $1.6 billion incurred to date.
Bristol-Myers Squibb (BMY) furnished materials related to its third-quarter 2025 results. The company posted an earnings press release and an investor presentation on its website, and furnished them as Exhibits 99.1 and 99.2. The materials reference non-GAAP metrics, with reconciliations included in the press release.
The presentation supported the company’s Q3 2025 conference call and webcast at 8:00 a.m. Eastern time. Information furnished under Item 7.01, including Exhibits 99.1 and 99.2, is not deemed filed under the Exchange Act.
Cari Gallman, Executive Vice President and General Counsel at Bristol-Myers Squibb Company (BMY), reported a set of insider transactions on 10/02/2025. The filing shows 4,558 restricted stock units (RSUs) treated as acquired under rule code M and converted to shares upon vesting; those RSUs convert one-for-one into common stock when vested. The filing also discloses the disposition of 2,332 shares withheld to cover taxes on the award at an average price of $45.73. After these transactions, Ms. Gallman beneficially owns 11,066 shares of common stock.
The RSUs vest in three equal installments beginning on 10/02/2024, and the reported transactions reflect routine compensation vesting and tax-withholding actions rather than open-market purchases.
Phyllis R. Yale, a director of Bristol-Myers Squibb Company (BMY), reported a transaction dated 09/30/2025 on a Form 4. The filing shows acquisition of 776.053 Deferred Share Units which will convert to shares of common stock upon settlement. After this transaction the reporting person beneficially owned 37,734.687 shares, a total that the filing says includes deferred compensation and dividends reinvested. The reported price for the deferred units is $0. The Form 4 is signed by an attorney-in-fact on behalf of Ms. Yale and dated 10/02/2025.
Michael R. McMullen, a director of Bristol-Myers Squibb Company (BMY), reported an acquisition on 09/30/2025 of 776.053 Deferred Share Units. Each Deferred Share Unit will convert into one share of common stock upon settlement, and the units become settleable when the reporting person ceases to be a director or at a previously specified future date. Following this transaction and prior deferred holdings, the filing shows the reporting person beneficially owns 10,076.278 shares (direct). The Form 4 was filed by an attorney-in-fact and signed on behalf of Mr. McMullen on 10/02/2025.
Peter J. Arduini, a director of Bristol-Myers Squibb Company (BMY), reported acquisition of 748.337 Deferred Share Units on 09/30/2025. Each Deferred Share Unit will convert into one share of common stock upon settlement; the units become settleable when the reporting person ceases to be a director or at a previously specified future date. After this transaction the filing shows the reporting person beneficially owns 64,620.164 shares (this total includes deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
David V. Elkins, Executive Vice President and Chief Financial Officer of Bristol-Myers Squibb Company (BMY), reported a sale of 56,000 shares of BMY common stock on 09/02/2025 at a weighted average price of $47.33 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2025, and the reported sale prices ranged from $47.075 to $47.820. After the transaction, Mr. Elkins beneficially owned 167,379 shares directly. In addition, the filing reports an indirect holding of 283.4 shares through the BMS Savings and Investment Program. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and includes an undertaking to provide detailed per-price sale information upon request.
Wendy Short Bartie, EVP Corporate Affairs of Bristol-Myers Squibb Company (BMY), reported securities transactions on Form 4 showing restricted stock units vesting and shares withheld for taxes. On 09/01/2025, 1,235 restricted stock units converted into 1,235 shares of common stock (reported as acquisition at $0) under a vesting schedule that began 09/01/2023 and vests in four equal installments. Simultaneously, 632 shares were withheld to satisfy tax-withholding obligations at an indicated price of $47.18 per share. After these events, Ms. Bartie directly beneficially owned 5,669 shares.
Bristol-Myers Squibb Co. (BMY) filed a Form 144 notifying the proposed sale of 56,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of $2,648,800.00. The filing reports total shares outstanding of 2,035,435,838 and an approximate sale date of 09/02/2025. The shares to be sold were acquired over 2021–2023 through stock option exercises and restricted stock vesting, with acquisition amounts listed by date (e.g., 2,976 on 08/12/2021; 19,326 on 09/13/2022). No securities were reported sold in the past three months.
Bristol-Myers Squibb (BMY) – Form 4 filing: EVP & Chief Medical Officer Cristian Massacesi reported the grant of 204,691 Restricted Stock Units (RSUs) on 08/01/2025. Each RSU converts into one share of BMY common stock upon vesting at no exercise cost.
Key terms:
- Vesting schedule: 25 % each year on the 1st–4th anniversaries of the grant date (first tranche 08/01/2026; final tranche 08/01/2029).
- Ownership after grant: Massacesi now holds 204,691 derivative securities directly.
- Transaction code: “A” (award) – no open-market purchase or sale occurred.
The award represents <0.01 % of BMY’s ~2.1 bn shares outstanding, so dilution is immaterial. The filing signals long-term incentive alignment but has no immediate earnings or cash-flow impact; therefore market effect should be minimal.